key: cord-0862169-esebte60
authors: Ben-Tov, Amir; Banon, Tamar; Chodick, Gabriel; Kariv, Revital; Assa, Amit; Gazit, Sivan
title: BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Inflammatory Bowel Disease: Preliminary Real World Data during Mass Vaccination Campaign
date: 2021-07-02
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.06.076
sha: e81e39417c74362bf38c05b953fc7ce827af4722
doc_id: 862169
cord_uid: esebte60

nan

A two dose regimen of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) has demonstrated 95% efficacy in preventing COVID-19 in phase III placebo-controlled randomized clinical trial 1 and in real-world data analyses. 2, 3 Patients with inflammatory bowel disease (IBD) treated with immune-modifying agents are considered partially immunosuppressed, and thus the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) recommend that patients with IBD should be vaccinated against COVID-19 and that vaccination should not be deferred in patients receiving immune-modifying therapies. 4 As patients with immune conditions (including IBD) were excluded from the COVID-19 vaccine clinical trials, it is important to describe accumulating real world data. 5 In Israel, patients with IBD were given priority for early vaccination in the campaign, which is, as of June 23 th 2021, the most extensive worldwide (63.6% of the total population received at least two dose and 59.5% of the population was fully vaccinated). 6 This study is a preliminary report of the effect of mass vaccination in patients with

This retrospective cohort study was conducted using data from Maccabi Healthcare Services (MHS) central computerized database. MHS is the second largest statemandated healthcare provider in Israel, covering more than 2.5 million members (25% of the population) and is a representative sample of the Israeli population.

To evaluate vaccine effectiveness, this study included BNT162b2 mRNA COVID-19 vaccinees aged 16 years and older from the MHS IBD registry and matched patients (1:3) who were vaccinated between December 19 th 2020 and March 10 th 2021.

Individual matching was performed based on sex, birth year, coexisting comorbidities J o u r n a l P r e -p r o o f and month of first vaccination dose. IBD status was defined according to the MHS IBD registry based on physician diagnosis and dispensed medications. 7 Excluded from the analysis were patients with a history of a positive PCR or diagnosis of COVID-19 any time prior to the first BNT162b2 vaccination. All eligible patients were required to have a minimum of 30 days of follow-up post second vaccine dose date, referred to as the "index date", to observe study outcomes.

Retrospective follow-up lasted from index date until April 11, 2021 (details in Supplementary Text S1).

The study protocol was approved by the MHS Ethics Committee. In a secondary analysis, internal comparisons were made among IBD patients. Cox regression analyses were performed and evaluated positive PCR outcomes >7 days and >14 days post second vaccine dose. Covariates in the models included age, sex, IBD type, and whether patients were on immunosuppressive treatment (binary variable) 3 months prior to index date. Tables   Table S1a . Study population characteristics Table S1b . Positive PCR characteristics in patients with IBD >7 days and >14 days post 2 nd vaccine dose Table S1c . Characteristics of patients with IBD Table S2a . Cox multivariate regression analysis evaluating time to positive PCR outcome in IBD patients >7 days post 2 nd vaccine dose Table S2b . Cox multivariate regression analysis evaluating time to positive PCR outcome in IBD patients >14 days post 2 nd vaccine dose

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of realworld data

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Looking beyond COVID-19 vaccine phase 3 trials

COVID-19) Vaccinations -Statistics and Research -Our World in Data

establishing a registry for inflammatory bowel disease patients in maccabi healthcare services -joint project between hospitals, epi-iirn group and community medicine

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies